Molecular Formula | C18H29NO3.ClH |
Molar Mass | 343.892 |
Boling Point | 448ºC at 760 mmHg |
Flash Point | 224.7ºC |
In vitro study | Levobetaxolol produced potent antagonistic activity at cloned human β1 and β2 receptors, as well as Guinea pig atrial β1, tracheal β2 and rat colon β3 receptors, with an IC50 of 33.2 nM, respectively, 2970 nM and 709 nM. Levobetaxolol (K I = 16.4 nM) was more effective than Dextrobetaxolol(K I = 2.97 μm) in inhibiting Isoproterenol-induced cAMP production in human non-pigmented ciliary epithelial cells. Levobetaxolol (applied topically) protects retinal ganglion cells from different types of injury. Levobetaxolol acts on the rat cortex, replacing [ |
In vivo study | Levobetaxolol(150 mg) was more effective than Dextrobetaxolol in macaques with ocular hypertension, reducing IOP by 25.9 percent. Levobetaxolol(20 mg/kg) treatment of light-induced retinopathy in rat models significantly protected retinal function, resulting in significant thickening of the RPE and outer nuclear layer. Levobetaxolol(20 mg/kg) caused a 10-fold upregulation of bFGF and a 2-fold upregulation of CNTF mRNA levels, all of which inhibited retinal degeneration in many species. |